Skip to comments.Fresh hep C hope
Posted on 04/25/2010 6:39:22 PM PDT by neverdem
A new kind of compound to treat hepatitis C is showing promise in early clinical trials. The treatment, being developed by Bristol-Myers Squibb (BMS), was found to be very effective at lowering viral load, both in a Phase I trial published this week in Nature, and in early results of a Phase IIa trial presented at the European Association for the Study of the Liver's annual meeting in Vienna last week.
Current HCV therapy is not ideal. The standard treatment is with an interferon and the antiviral agent ribavirin, but is only effective in around half of all patients and is plagued with side-effects. Various new antiviral agents are under development, including protease inhibitors and polymerase inhibitors, and BMS-790052 works against a new target, the NS5A protein.
'If we are to replace interferon with small molecules, we would need at least two if not three, so we set out to look for new inhibitors,' explains Nick Meanwell of BMS's research team. 'We ran a chemical genetics screen, and found a single interesting inhibitor whose resistance mapped to the NS5A protein. We don't know what this protein actually does - it's very enigmatic! We took that lead compound, and after some very interesting chemistry we finessed out the pharmacophore, and that led to the final molecule which is now in clinical trials.'
BMS-790052 could offer a new treatment option for hepatitis C
The hepatitis C virus has many different genotypes. The initial screen was run on type 1b, and BMS chemists got to work to find an analogue that was active more broadly. 'We had to understand how to inhibit type 1a, which was quite a challenge, but we solved it,' says Meanwell. 'Typically, there is an effect on viral load by the 12 hour point, and at the highest dose we are reducing viral load in plasma by almost 99.99 per cent.'
The compound also seems to be effective against other genotypes. The next step, says Meanwell, is a combination study where it will be given alongside the company's protease inhibitor BMS-650032, but without the standard interferon and ribavirin, which was given to patients in the reported trials. 'It's a small study and very early days, but we hope to release results towards the end of the year,' he says.
'It looks a most interesting compound,' says Geoff Dusheiko of the centre for hepatology at University College London, UK. 'Other groups have worked on NS5A inhibitors that have not shown the same level of potency, which is crucial. It looks like it has fairly broad activity across HCV genotypes, which would also be an important breakthrough.'
That second link is for clinical trials recruiting patients if anyone knows folks with HCV.
My brother was infected through transfusion following a near fatal motorcycle accident in 1984. We lost him last year, after a long battle. The treatments and clinical trials were not useful and debilitating in his case, though none of us are complaining after getting an additional quarter century of his company. Glad to see progress for others, as he would have been.
Sorry about your brother. I have hep c & tried the treatments which made me sick & did nothing for me. I was told in 82 I had non A non B hep. I’ve been living with it ever since. I don’t know if I would even bother trying another treatment. I was told there is no cure for hep c yet I see people claiming they’re cured. I thought it went into remission.
I'm not tired or achey sick or anything and I've had it for 35 years or more. Figure I've got my moneys worth living in Alaska anyway. I'll probably drop over from heart attack like all my relatives in mid 60's;;;; so I got 7 more years;;; life is good. Every day is another lucky one.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.